Diagnostics News and Research

RSS

Researchers identify new gene that can influence person's risk of developing epilepsy

Vanderbilt University researchers have identified a new gene that can influence a person's risk for developing epilepsy. The findings, reported in the March 29 Proceedings of the National Academy of Sciences, could improve molecular diagnostic tools and point to novel therapeutic targets for epilepsy.

5 Apr 2011

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.

5 Apr 2011

Caliper introduces novel fluorescent imaging agent for pre-clinical research

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery, life sciences research and molecular diagnostics, today announced the launch of XenoLight RediJect COX-2 Probe, a novel fluorescent imaging agent for pre-clinical research that specifically detects the cyclooxygenase-2 biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications.

5 Apr 2011

Medical industry veteran set to play key role as Microvisk gears up to launch Smartstrip®

Microvisk Technologies, the developer of a handheld system to monitor the blood clotting status of patients taking the drug Warfarin, today announced that it has strengthened its Board with the appointment of medical industry veteran, Bill Moffitt, as Chairman and Peter Whitehouse as CFO.

4 Apr 2011

Pronto to distribute Signal's Myeloma Prognostic Risk Signature test in Israel

Signal Genetics, the parent company of Myeloma Health LLC, and Pronto Diagnostics Ltd, both of which are privately held predictive genetic testing companies focused on oncology, announced that they have entered into a Distribution Agreement whereby Pronto will be the exclusive representative and distributor for Signal's Myeloma Prognostic Risk Signature (MyPRS) test in Israel.

4 Apr 2011

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.

From Quest Diagnostics 4 Apr 2011

Quest Diagnostics completes Athena Diagnostics acquisition

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced it has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders, from Thermo Fisher Scientific.

From Quest Diagnostics 4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

Esaote acquires 3mensio

Esaote International NV and 3mensio Medical Imaging BV have entered into an agreement pursuant to which Esaote acquires 3mensio in order to expand its leading role in healthcare information technology.

4 Apr 2011

Abbott's XIENCE V Coronary Stent System data presented at ACC meeting

A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's market-leading XIENCE V Everolimus Eluting Coronary Stent System.

4 Apr 2011

Positive results from Abbott's ABSORB device trial in coronary artery disease

Abbott today announced positive one-year results from 101 patients enrolled in the second phase of the ABSORB trial evaluating the world's first drug eluting Bioresorbable Vascular Scaffold for the treatment of coronary artery disease.

4 Apr 2011

QIAGEN to acquire Cellestis

QIAGEN N.V. has reached an agreement to acquire Cellestis Limited for approximately A$341 million in cash, providing QIAGEN with access to a novel "pre-molecular" technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.

From QIAGEN Manchester Limited 4 Apr 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Recent releases in Global Health

A Lancet Infectious Diseases editorial describes the growing public concerns over a global rise in antimicrobial resistance. "Bearing in mind that our objective is to contain antibiotic resistance rather than eradicate it, several policies could be adopted to help guarantee a future for antibiotics," the editorial states, adding, "We need reliable data to tackle antibiotic resistance.

2 Apr 2011

Brain Canada issues statement reinforcing need for government support for brain research funding

Brain Canada today issued a statement reinforcing the pressing need for targeted Federal government support for brain research funding in Canada.

2 Apr 2011

Nipro Diagnostics recognized with SFMA Manufacturer of the Year Award

Nipro Diagnostics, Inc., a leading manufacturer and marketer of diabetes monitoring and management products, has been named the South Florida Manufacturer of the Year, in the 200+ employee category, by the South Florida Manufacturers Association.

2 Apr 2011

Study findings on novel ST2 cardiac biomarker to be presented at ACC 2011

A novel cardiac biomarker, ST2, will be highlighted in three presentations at the American College of Cardiology in New Orleans this week.

1 Apr 2011

Researchers study role of acetylation in Alzheimer's disease

Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer's disease and related disorders. The findings were published in the latest issue of Nature Communications.

1 Apr 2011

Invida, Roche partner to commercialize primary care products

Invida Group Pte Ltd, the leading specialty pharmaceutical company focused on the commercialization of healthcare products throughout Asia Pacific, today announced that it has entered into a partnership agreement with Roche for the commercialization and marketing of that company's primary care portfolio throughout Korea.

1 Apr 2011

CPRIT awards $12.6M grant to Gulf Coast Consortia to develop new cancer treatments

The Gulf Coast Consortia has been awarded a grant of more than $12.6 million from the Cancer Prevention Research Institute of Texas to launch a collaborative program that brings together researchers with the common purpose of developing new cancer treatments.

1 Apr 2011